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ABSTRACT 
AIM: Few personalized medicine investigations have been conducted for mental health. We aimed to generate and 
validate a risk tool that predicts adult Attention-Deficit/Hyperactivity Disorder (ADHD). 
METHODS: A composite risk calculator was generated in a population cohort (ALSPAC – UK, 5113 participants, 
birth to age 17) using childhood clinical and sociodemographic data with internal validation. The risk tool was 
externally validated in the E-Risk cohort (UK, 2040 participants, birth to age 18), the 1993 Pelotas Birth Cohort 
(Brazil, 3911 participants, birth to age 18), and the MTA clinical sample (US, 476 children with ADHD and 241 
controls followed for 16 years).  
RESULTS: In the generating sample, the Area Under the Curve (AUC) for predicting adult ADHD was ⋅82 (95% 
confidence interval [CI], ⋅80 to ⋅83). In the UK birth cohort test sample, AUC was ⋅75 (95% CI, ⋅71 to ⋅78). In the 
Brazilian birth cohort test sample, AUC was significantly lower – ⋅57 (95% CI, ⋅54 to ⋅60). In the clinical trial test 
sample, AUC was ⋅76 (95% CI, ⋅73 to ⋅80). The model did not predict adult Anxiety or Major Depressive Disorder. 
An open-source on-line risk calculator was generated for clinical use. 
CONCLUSIONS: The risk tool based on childhood characteristics specifically predicts adult ADHD in European 
and North-American population-based and clinical samples with comparable discrimination to commonly used 
clinical tools in internal medicine and higher than most previous attempts for mental and neurological disorders. 
However, its use in middle-income settings requires caution.   
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Introduction  
Attention-deficit/hyperactivity disorder (ADHD) is consistently associated with an increased risk of several adverse 
health and social outcomes, including poor education achievement, risky sexual behaviors and premature mortality  
(Cortese et al., 2013, Chang et al., 2014, Dalsgaard et al., 2015, Faraone et al., 2015). ADHD might begin in 
childhood and persist throughout adulthood, or it may remit spontaneously in around half of the cases (Caye et al., 
2016b). Recent evidence suggested that subthreshold symptoms can get worse over time, causing the emergence of a 
full-blown syndrome only in adulthood (Caye et al., 2017), although the topic is still under debate in the literature 
(Cooper et al., 2018, Manfro et al., 2018). Although some risk factors for the persistence or emergence of adult 
ADHD are known (Caye et al., 2016b, Caye et al., 2016c), the attending psychiatrist is currently unable to correctly 
predict the course of the disorder based on clinical assessments of children or to propose a preventive intervention 
for those at risk. 
One issue might be the inability to combine what is already known about risk factors. Although mental disorders 
arise from multiple risk factors, previous studies frequently define risk for targeted preventive interventions on the 
basis of a single risk factor, for instance, an affected first-degree relative or presence of subthreshold symptoms 
(Brent et al., 2015, Taylor et al., 2015, Buntrock et al., 2016). Meanwhile, multivariable risk scores such as the 
Framingham risk score for cardiovascular disease have been one of the main frameworks for the study of preventive 
strategies in other areas of medicine. 
Our aim was to develop and validate a multivariable risk calculator that estimates the individual risk of ADHD in 
late adolescence/young adulthood based on childhood characteristics. ADHD lends itself easily to the development 
of a risk calculator for the following reasons: First, its adverse health and social consequences are well established 
(Asherson et al., 2016). Second, it is widely accepted that its roots are in early childhood, although some argue the 
full syndrome might develop later in some individuals (Moffitt et al., 2015, Agnew-Blais et al., 2016, Caye et al., 
2016a). Third, being a neurodevelopmental disorder, early intervention has the potential to change brain 
development and improve later clinical outcomes (Shaw et al., 2006). Fourth, there is substantive evidence to 
support a priori hypotheses about specific childhood risk factors (Caye et al., 2016b). 
Method 
Our methods follow well-established probability models in medicine and recommendations of the Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement (Collins 
et al., 2015). We developed the predictive model in one a priori selected sample and validated it independently in 
three external samples (TRIPOD analysis type 3). We selected the Avon Longitudinal Study of Parents and Children 
(ALSPAC) cohort as the generating sample based on the following a priori defined criteria: population-based 
sample, largest sample.  
Samples and participants  
ALSPAC 
The (ALSPAC) is a prospective birth cohort study in the UK. Pregnant women with expected delivery dates 
between April 1st, 1991 and December 31st, 1992, were invited to participate. Ethical approval for the study was 
obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Further details 
on assessments can be found elsewhere (Boyd et al., 2013). Please note that the study website contains details of all 
the data that is available through a fully searchable data dictionary (http://www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/). For the current study, we included 5113 subjects that were assessed for ADHD in 
childhood (age 7 or 10) and in the last available assessment (age 17).  
E-Risk 
The Environmental Risk (E-Risk) Longitudinal Twin Study is a prospective birth cohort study designed to represent 
the UK population. In 1999-2000, investigators enrolled 1116 families with same-sex 5-year-old twins (N=2232) 
born from January 1st, 1994 to December 4th,1995 (Moffitt and Team, 2002). The study was approved by the Joint 
South London and Maudsley and the Institute of Psychiatry Research Ethics Committee, and parents gave informed 
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written consent. Further details can be found elsewhere (Moffitt and Team, 2002). For the analyses, we included 
2040 subjects with data on ADHD in childhood (ages 5, 7, 10 or 12) and in young adulthood (age 18). 
 
Pelotas 1993 
 
The 1993 Pelotas Birth Cohort is a prospective longitudinal birth cohort set in Brazil. In 1993, mothers of all 
children born in the city of Pelotas were contacted and 5249 children were enrolled. The study was approved by the 
institutional review board of the Federal University of Pelotas, and participants provided written informed consent. 
Further information on the cohort design can be found elsewhere (Goncalves et al., 2014). For the current study, we 
included 4039 participants that had complete ADHD assessment at age 18 to 19 years old. 
 
MTA 
 
The Multimodal Treatment Study of Children with ADHD (MTA) is the largest clinical trial and observational 
follow up conducted with children with ADHD. In the first phase of the study, investigators enrolled 579 children 
aged 7 to 10 years old with ADHD and assigned them to 14 months of one of four groups of management. Two 
years after baseline, 515 consented to enter an observational follow-up and a local normative comparison group of 
289 classmates (258 without ADHD) was added. Assessments were conducted at 12, 14, and 16 years after baseline. 
Informed consent (parental permission and child assent) was obtained for all participating families, using forms 
approved by both local institutional review boards and the NIH. Detailed design and methods have been presented in 
previous publications (1999). We included 717 subjects with any complete ADHD assessment in young adulthood 
(mean age 24). 
 
Assessment and definition of the outcome variable 
In each sample, the outcome was a dichotomous ADHD definition in late adolescence or young adulthood. In 
ALSPAC, participants’ parents completed the hyperactive subscale of the Strengths and Difficulties Questionnaire 
(SDQ-HS) at 17 years of age. The scale showed excellent discrimination against a DSM-IV diagnosis derived from 
the Development and Well-Being Assessment (DAWBA) conducted in a subsample of 1673 participants (AUC = 
⋅89, 95% CI ⋅81 to ⋅96). The best cut-off score to define diagnosis was at least 6 points on the SDQ-HS (sensitivity = 
83⋅3%, and specificity = 83⋅3%). In the E-Risk, ADHD was ascertained at age 18 years using structured interviews 
based on full DSM-5 criteria (Agnew-Blais et al., 2016). In the MTA sample, ADHD symptoms were derived from 
the parents´ Conners Adult ADHD Rating Scale (CAARS). At least five DSM-5 symptoms of inattention and/or 
hyperactivity were required for the symptom criteria. Impairment was evaluated with the Impairment Rating Scale 
(IRS), which has strong psychometrics and accurately identifies impairment in adults with ADHD (Sibley et al., 
2012). This diagnostic approach was chosen because it has better diagnostic accuracy than a semi-structured 
interview in this sample (Sibley et al., 2017b). In the Pelotas cohort, trained psychologists interviewed the 
participants at 18 to 19 years old with a structured interview for ADHD based on DSM-5 criteria (Caye et al., 
2016a). A strict age-at-onset criterion was not required to define ADHD in young adulthood to take into account 
recent evidence suggesting a significant prevalence of late onset ADHD presentation (Moffitt et al., 2015, Agnew-
Blais et al., 2016, Caye et al., 2016a). 
Assessment and definition of predictor variables 
We selected the following predictor variables assessed in childhood: female sex, socioeconomic status (SES), 
mother’s depression, intelligence quotient, maltreatment, ADHD symptoms, depressive symptoms, oppositional 
defiant behavior and conduct disorders, and single parent family. All predictors were collected before age 12, with 
the exception of intelligence in Pelotas, which was measured at age 18. Their selection was based on extensive 
review of previous reports in the literature and a meta-analysis conducted by our group (Moffitt et al., 2015, Agnew-
Blais et al., 2016, Caye et al., 2016a, Caye et al., 2016b). We have included all variables that were available across 
the four samples with some level of comparability, without performing univariate analysis or stepwise techniques 
for variable selection. Definition of predictors was defined a priori according to relevant literature in the field. 
Further details are provided in on-line eTable 1. 
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Statistical analysis 
When developing a predictive model in multiple samples, a recommended approach consists in selecting and tuning 
the best model in one a priori selected sample and assessing its performance fo in the remaining independent 
samples for external validity. Because the evaluation of internal performance within the same sample where the 
model was derived is affected by overfitting, internal validation optimism correction should be performed. Among 
the most accepted techniques for internal validation is bootstrap resampling. 
We have developed the predictive model in the ALSPAC cohort. We ran a logistic regression including outcome 
(ADHD at last assessment) as the dependent variable and all eligible predictor variables as covariates. We inspected 
linearity assumptions of continuous variables by plotting the predictor and the logit of the outcome, and trough Box-
Tidwell regressions. We derived the model using linear splines of equal sample sizes (with knots at 25th, 50th, and 
75th percentiles) in the ADHD symptoms variable, and this model had better fit indexes (AIC, BIC). Multiple 
imputation with chained equations (10 imputations) using the remaining predictors was used to deal with missing 
values in the predictor variables. We used a fixed number of 10 iterations and assessed convergence with trace plots. 
In the ALSPAC cohort, for each of the 1000 bootstrap resamples, we have performed pooled regression coefficient 
estimates and variance across imputations with the command mi estimate in Stata (Rubin, 1987). We evaluated the 
predictive discrimination of the probability model calculating the area under the receiver operating characteristic 
curve (c statistic) of the estimated probability against the actual outcome as an index of model performance. We 
have assessed optimism of internal validation with bootstrap inference using 1000 replications with the R package 
rms (Harrell et al., 1996). We have assessed internal and external model calibration with calibration curves, plotting 
predicted probabilities against observed frequencies. Extreme predictions at the right end of the distribution (highest 
risk) including less than 1% of the sample at risk were excluded of the calibration analyses to avoid instability of the 
estimates, and these ranges are not shown in each graph. Multiple imputation and model generation were conducted 
in Stata MP 13.0. Finally, we tested the predictive discrimination of the same predictors using Machine Learning 
approaches with the R package caret (see eMethods).  
We performed several sensitivity analyses to assess the robustness of our findings. We analyzed the performance 
(measured by the c-statistic) of the model among individuals who endorsed a very low number of ADHD symptoms 
at baseline (operationalized as equal or below the median of each population) in ALSPAC, E-Risk and Pelotas 
samples. We had also analyzed the performance (measured by the c-statistic) of the model excluding one variable at 
each time. Finally, we present the variation of the predicted probability within fixed levels of ADHD symptoms to 
assess the contribution of the remaining variables to the model. 
Results 
The number of participants with a dichotomous definition of adult ADHD and the frequency of childhood predictors 
in each sample can be found in Table 1.   
Performance of the predictive model in the generating sample 
All variables entered in the probabilistic model were used for the calculation of the estimated risk of the individual 
(Table 2). Only ADHD symptoms were corrected with splines. The predictive model discriminated between adult 
ADHD vs. no adult ADHD with an AUC of ⋅82 (Bootstrap-corrected 95% CI, ⋅80 to ⋅83, p < .001), which indicates 
very good discrimination (Figure 1). Correction for optimism with bootstrapping yielded an AUC of ⋅81. The 
calibration plot showed that predicted probability and observed frequency of adult ADHD closely agreed throughout 
the entire range of risk (0 to around 50% - Figure 2). The bias-corrected calibration curve was nearly identical 
(eFigure 1). The AUC varied within a range of ⋅74 to ⋅82 in sensitivity analyses taking out one predictor at a time 
(eTable 2 in Supplemental material). Proposed probability cut-offs are presented with sensitivity, specificity, 
positive predictive value and negative predictive value in eTable 3 in Supplemental material. 
Performance of the predictive model in a validating cohort sample in the same country 
In the E-Risk study, the predictive model discriminated between adult ADHD vs. no adult ADHD with an AUC of 
⋅75 (Bootstrap-corrected 95% CI, ⋅71 to ⋅78, p < .001), which indicates fair discrimination (Figure 1). The 
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calibration plot showed reasonable agreement between predicted and observed event frequencies, especially in the 
lower range of risk (Figure 2). The discrimination was the same when restricting the sample to randomly selected 
non-siblings (eTable 4 in Supplemental material).  
Performance of the predictive model in a validating sample in a middle-income country 
In the Pelotas cohort, the predictive model discriminated between adult ADHD vs. no adult ADHD with an AUC of 
⋅57 (Bootstrap-corrected 95% CI, ⋅55  to ⋅60, p < .001), which indicates poor discrimination (Figure 1). There was 
low agreement between estimated probability and observed frequency of the outcome (Figure 2). 
Performance of the predictive model in a validating clinical sample in a country with similar income 
In the MTA, the predictive model discriminated between adult ADHD vs. no adult ADHD with an AUC of ⋅76 
(Bootstrap-corrected 95% CI, ⋅73 to ⋅80, p < .001) (Figure 1). The calibration plot showed that predicted probability 
and observed frequency of adult ADHD closely agreed throughout the entire range of risk (0 to around 70% - Figure 
2), although the model had underestimated event frequency consistently. 
Performance of the predictive model within participants with very low endorsement of ADHD symptoms in 
childhood 
We tested the performance of the model for predicting late-onset ADHD in population samples, among only 
participants that endorsed few ADHD symptoms in childhood – the median or lower number of symptoms in their 
respective populations. The model had fair discrimination in these subgroups, except for the Pelotas sample in which 
the model already had poor discrimination (Table 3).  
Performance of the predictive model removing one predictor at a time 
We tested the model taking out one predictor at a time (eTable 2). The most relevant individual predictor was the 
level of ADHD symptoms in childhood. However, the model still had fair performance in the model without ADHD 
symptoms in childhood, with an AUC of ⋅74 (95% CI, ⋅72 to ⋅76, p < .001).  
Variation of the predicted probability within fixed levels of ADHD symptoms 
We assessed the predicted probabilities of an adult ADHD diagnosis at any fixed level of ADHD symptoms, 
considering maximum variation of the remaining factors (see eFigure 2). The observed variance indicates that 
ADHD symptoms are not the only relevant predictive factor in the model. These findings analyzed together clearly 
indicate that this is not a model based on just one variable.     
Specificity of the predictive model in predicting ADHD 
Considering that E-risk is the population cohort with the most comprehensive assessment of comorbid mental 
disorders, we tested model’s discrimination predicting adult Anxiety and Major Depressive Disorder. The 
performance was significantly lower than for ADHD, showing specificity for ADHD compared to other forms of 
adult psychopathology (eTable 5 in Supplemental material). 
Risk calculator and robustness of findings  
Predictive discrimination estimates using three different machine-learning approaches were almost the same (see 
eTable 6 in Supplemental material). In a secondary analysis, we also have developed one comprehensive predictive 
model with all samples at once, using site as one more predictor variable (see eTable 7; eFigure 3). A risk calculator 
can be found at http://www.ufrgs.br/prodah/adhd-calculator/.  
Discussion 
The widespread use of tools that predict clinical outcomes in medical practice has promoted development and 
testing of preventive interventions, but this approach has been rarely attempted for mental health (Bitton and 
Gaziano, 2010). We generated a probability model to predict adult ADHD in a large birth cohort in the UK, with 
very good discrimination – AUC of ⋅81 after optimism correction – and calibration. This performance compares to 
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the most used clinical tools in Medicine (Morrow et al., 2000). Recent attempts for mental health reported risk 
scores with good calibration (Fusar-Poli et al., 2017, Hafeman et al., 2017). These studies lacked, however, a 
consistent external validation with completely independent samples.  
Our next step was to validate the score in independent samples. First, we tested the score in another UK birth cohort, 
the E-Risk. Its performance for predicting adult ADHD was similar. This is an important finding because several 
risk models in mental health did not replicate well even in samples from similar settings (Kivipelto et al., 2006, 
Anstey et al., 2014). Since data generated in population samples frequently do not translate to clinical samples 
(Weissman et al., 2011), we tested the performance of the score in the MTA study, the largest clinical trial ever 
conducted for ADHD. As for ALSPAC and E-risk, the score worked well with good discrimination and calibration.  
We then tested the score in a third birth cohort from Brazil. We observed that the score was much less accurate with 
an AUC of ⋅57. This finding is not surprising, since previous evidence suggests that the predictive discrimination of 
risk tools is lower in diverse sociocultural and ethnic populations (Chia et al., 2015). However, since predictor 
factors assessment in Pelotas was the most heterogeneous, observed low discrimination might have been an effect of 
measurement error.  
Models that predict a diagnosis of chronic disorders often include premorbid signs and symptoms of the disease as 
predictive factors. For example, the factor that increased discrimination the most in the recently published calculator 
for psychosis was the index diagnosis when presenting to secondary care, where Psychotic disorders had the greatest 
weight compared to other disorders such as mood disorders (Fusar-Poli et al., 2017). Although this is a valid 
approach, other variables must also add to prediction, otherwise models would be tautological. Therefore, we also 
validated the score in subjects with low endorsement of ADHD symptoms in childhood. The performance was good 
even in this sensitivity analysis. In addition, we assessed probabilities of an adult ADHD diagnosis at any fixed level 
of ADHD symptoms, allowing maximum variation of the remaining factors. Finally, we checked discrimination of 
the model removing each factor at once. Findings suggested that although ADHD symptoms are the most important 
overall predictor, the complete model works as a necessary refinement and a model without ADHD symptoms has 
good discrimination as well.  
We also conducted other secondary analyses to assess robustness of our findings. We tested the impact of using 
other statistical methods on our results. We observed that the discrimination of the prediction models remained 
stable regardless of chosen statistical methods. Finally, we tested the hypothesis of whether the score was specific 
for the prediction of ADHD. This is an important proof-of-concept: personalized medicine has always been a 
challenge for the area of psychiatry, as it has been shown consistently that most identified biomarkers and risk 
factors associated with one mental disorder are also associated with several others (Cross-Disorder Group of the 
Psychiatric Genomics et al., 2013). We observed that the score was specific for ADHD, not predicting Major 
Depressive Disorder or Anxiety Disorders.  
Previous cohort investigations included in the present study did not find significant childhood DSM dichotomous 
ADHD diagnosis in the trajectory of late onset ADHD (Agnew-Blais et al., 2016, Caye et al., 2016a). Thus, it might 
seem surprising that childhood ADHD symptoms predict adult ADHD. The MTA report also highlighted the 
importance of child ADHD subthreshold symptoms in adult ADHD in cases where formal DSM diagnosis were not 
found in childhood (Sibley et al., 2017a). Since this approach was not the main focus of previous cohort studies 
(ADHD subthreshold symptoms), this might explain why childhood ADHD symptoms predict adult ADHD even in 
cohorts where childhood dichotomous diagnosis was not relevant for adult ADHD.  
Our findings should be interpreted considering a set of limitations. First, the design and assessments of different 
samples were not uniform, limiting the discrimination of the score in the validating samples. Adult ADHD, for 
instance, was measured with a scale rather than with a structured interview in the generating sample, but not in the 
validating samples. It is possible, therefore, that the proposed estimated predictive discrimination in validating 
samples might actually be an underestimation. Further validating efforts with assessments that more closely 
resemble those of the generating sample might observe higher AUCs. However, this could also be seen as strength 
of the study, since observed discrimination indices are considered good, even with different methodologies 
implemented in individual studies. Second, there was attrition in the generating sample’s assessments. Nevertheless, 
potential selection bias does not appear to affect the prediction of outcomes in this cohort, as shown in previous 
publications (Boyd et al., 2013). Also, we have used multiple imputation techniques to deal with missing values. 
Third, the observed positive predictive value in selected cut-offs reaches a maximum of 61⋅8%, while the negative 
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predictive value is much higher throughout prediction. Although this might be considered insufficient, we ought to 
remember that the positive predictive value depends much on the prevalence of the studied condition, and we are 
working with population-based samples where the base rate of the condition is low. As a comparison, the 
Framingham risk score, that is also a tool developed in the general population, yields a positive predictive value of 
up to 30-40%. The risk score for Bipolar Disorder reports a positive predictive value of up to 32%, even among 
offspring of Bipolar patients (a high-risk sample). Fifth, it is important to note that other variables that are related to 
ADHD could have been part of the risk score like prematurity and ADHD in first degree relatives. However, they 
were not available for testing in the 4 data sets and our guide for risk factors was evidence-based guided by a 
previous meta-analysis (Caye et al., 2016b). Accordingly, the predicted probability provided by the model should be 
considered an estimate probability obtained with a pre-specified set of variables. 
What is the clinical utility of this score, provided that previous literature already has shown that most variables 
included in our model that are non-specific risk factors for mental disorders and ADHD symptoms in childhood, as 
expected, are key predicted risk factor for adult ADHD? No previous effort combined all these variables in a single 
risk calculator. Therefore, the only information that clinicians could offer was that some variables, like comorbidity 
with CD/ODD in childhood, increase the risk of persistence of ADHD. By using this calculator, attending clinicians 
can identify high-risk individuals to inform parents and guide decisions.  
Thus, we propose a multivariable risk model to predict ADHD in young adulthood based on childhood factors that 
has good discrimination in both population and clinical settings. Clinicians can use the model to guide long-term 
decisions based on identification of children at high risk for future adult ADHD diagnosis. Also, it provides a 
framework for testing the effectiveness of preventive interventions focused on high-risk individuals. Furthermore, 
the score might be used to identify at-risk individuals for investigating neurobiological features including brain 
development. The lower discrimination observed in a middle-income country urges the discussion of how globally 
generalizable are the risk models that are currently being widely used in clinical practice.  Indeed, even the well-
established Framingham cardiovascular risk model is being subjected to criticism for its wide variation in 
performance across different populations. Therefore, future attempts to improve the current model should include 
setting-specific recalibration analyses that should then be translated to specific risk calculators to be used across 
different settings. Also, we suggest that cohorts use more standardized methods of collection of predictors and 
outcomes in Psychiatry for the study of risk factors, so that we can disentangle whether failure to replicate is due to 
heterogeneity of methods or population. Hence, our work adds to the need for validation of risk models in low and 
middle-income countries. 
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Table 1. Frequency of young adulthood ADHD and of childhood predictors across the four samples 
 ALSPAC 
(n = 5113) 
E-Risk 
(n = 2040) 
MTA  
(n = 717) 
Pelotas 
(n = 4039) 
Adult ADHD 486 (9⋅5%) 166 (8⋅1%) 205 (28⋅6%) 492 (12⋅2%) 
Female sex 2619 (51⋅2%) 1071 (52⋅5%) 153 (21⋅3%) 2061 (51⋅0%) 
Socioeconomic status     
Upper 868 (18⋅6%) 401 (19⋅7%) 136 (18⋅9%) 763 (19⋅6%) 
Middle 2172 (46⋅4%) 966 (47⋅5%) 356 (50⋅7%) 1775 (45⋅6%) 
Lower 1637 (35⋅0%) 665 (32⋅7%) 210 (29⋅9%) 1358 (34⋅9%) 
Single parent 519 (11⋅8%) 450 (22⋅6%) 190 (26⋅5%) 882 (22⋅7%) 
ODD or CD 157 (3⋅4%) 602 (29⋅5%) 304 (43⋅6%) 275 (7⋅0%) 
Maltreatment     
Not detected 2084 (41⋅0%) 1609 (78⋅9%) 384 (55⋅3%) 2475 (67⋅0%) 
Probable 2568 (50⋅5%) 312 (15⋅3%) 279 (40⋅1%) 672 (18⋅3%) 
Severe 430 (8⋅5%) 119 (5⋅8%) 32 (4⋅6%) 548 (14⋅8%) 
Lifetime Depression of 
the mothera 
1850 (36⋅3%) 990 (48⋅5%) 326 (48⋅2%) 1881 (48⋅4%) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
IQ 106⋅9 (16⋅3) 98⋅9 (15⋅6) 103⋅1 (19⋅5) 96⋅5 (12⋅5) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Depressive Symptomsb 0 (1) 1 (2.5) 5⋅4 (6⋅7) 4 (4) 
Number of ADHD 
symptomsc 
2 (6) 1⋅5 (3⋅3) 8⋅3 (9⋅6) 4 (5) 
 
 
ADHD Attention-deficit hyperactivity disorder ODD Oppositional Defiant Disorder CD Conduct disorder 
SD Standard deviation IQR Interquartile range IQ Intelligence quotient 
a. Definition of lifetime depression of the mother was designed to be very sensitive, either by multiple 
assessments and/or by applying a very low threshold (further details on Table S1 of Supplementary 
material). 
b. ALSPAC: Number of DSM-IV depressive items endorsed. E-Risk, MTA: Children’s Depressive Inventory 
(CDI) score. Pelotas: Emotional subscale score of the SDQ. 
c. ALSPAC, E-Risk, MTA: number of DSM-IV ADHD items endorsed. Pelotas: Hyperactivity subscale score 
of the SDQ. 
Note: reported values before multiple imputation. Because each factor may have missing values, we report total 
number of participants and a proportion where the denominator is the total number of valid subjects. 
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Table 2. The probability model in the generating sample (n = 5113) 
Predictors OR (BC 95% CI) BC p-value 
Female sex ⋅72 (⋅58 - ⋅89) ⋅003 
Socioeconomic status - - 
Upper social class reference - 
Middle social class 1⋅58 (1⋅15 – 2⋅16) ⋅004 
Lower social class 1⋅55 (1⋅11 – 2⋅15) ⋅010 
Single parent family 1⋅19 (⋅90 – 1⋅58) ⋅215 
ADHD symptoms – 0-25th  3⋅77 (2⋅09 – 6⋅79) < ⋅001 
ADHD symptoms – 25-50th 1⋅19 (1⋅02 – 1⋅40) ⋅031 
ADHD symptoms – 50-75th 1⋅13 (1⋅05 – 1⋅22) ⋅001 
ADHD symptoms – 75-100th  1⋅18 (1⋅12 – 1⋅25) < ⋅001 
ODD or CD 1⋅81 (1⋅21 – 2⋅71) ⋅004 
Childhood maltreatment - - 
No detected maltreatment reference - 
Probable maltreatment 1⋅28 (1⋅01 – 1⋅64) ⋅045 
Severe maltreatment 1⋅35 (⋅93 – 1⋅95) ⋅115 
Depression of the mother 1⋅41 (1⋅13 – 1⋅75) ⋅002 
Intelligence quotienta  ⋅89 (⋅85 -  ⋅95) < ⋅001 
Depressive symptoms (z-score)b 1⋅00 (⋅92 – 1⋅10) ⋅940 
 
OR Odds Ratio; ODD Oppositional Defiant Disorder; CD Conduct Disorder; ADHD Attention-
deficit hyperactivity disorder 
BC Bootstrap-corrected 
a. We report the OR for a 10-point change in the intelligence quotient scale. 
b. Due to the OR of 1⋅00 for depressive symptoms, we have omitted this variable from the on-
line calculator. 
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Table 3. Performance of the score for individuals with very low ADHD childhood symptoms. 
 AUC BC 95% CI BC p-value 
ALSPAC (n = 2688) ⋅77 ⋅72 – ⋅82 < ⋅001 
E-Risk (n = 1099) ⋅78 ⋅71 - ⋅86 < ⋅001 
Pelotas (n = 2135) ⋅56 ⋅52 - ⋅60 < ⋅001 
 
BC Bootstrap-corrected  
ROC analyses were done only in participants with low endorsement of ADHD symptoms in childhood. Low 
endorsement was defined as median number of symptoms or below the median of their respective population 
(ALSPAC: 2 or less ADHD symptoms; E-Risk: 1 or 0 ADHD symptoms; Pelotas: the median or less than median 
(4) in the hyperactivity subscale of the SDQ). 
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eTable 1. Assessment of predictor variables. 
 ALSPAC E-Risk MTA Pelotas 
Intelligence quotient Weschler Intelligence Scale for Children 
version III, age 8 
Weschler Intelligence Scale for 
Children III-R, Age 12 
Weschler Intelligence Scale for 
Children version III, ages 7 to 10 
Weschler Adult Intelligence Scale, age 
18 
ODD or CD DSM-IV criteria, age 10 DSM-IV criteria, ages 5 to 12 (or rule) DSM-IV criteria, ages 7 to 12 (or 
rule) 
SDQ-C >= 7, age 11.a 
Depressive symptoms DSM-IV (DAWBA), z-score of 
symptoms, age 10 
CDI, z-score, age 12 CDI, z-score of mean reported 
symptoms, ages 7 to 12a 
SDQ-E rated by parents, z-score, age 11 
ADHD symptoms DSM-IV (DAWBA) rated by parents, 
number of symptoms, age 10 
DSM-IV rated by parents, z-score of 
number of reported symptoms, age 12 
DSM-IV (DISC-IV), ages 7 to 12, 
z-score of mean reported 
symptomsa, ages 7 to 12 
SDQ-H rated by parents, z-score, age 11 
Childhood maltreatment Physical, emotional or sexual abuse and 
maladaptive parenting according to 
previous definitions (Lereya et al., 
2015). None, probable or severe if 
neither, one or both were present (ages 
18 months to 7 years) 
None, probable or severe according to 
previous definitions (Caspi et al., 
2003), children’s ages 5 to 12. 
Parent-Child Relationship Scale 
answered by parents ages 7 to 12, 
grouped into none, probable or 
severe. 
None, probable or severe according to 
previous definitions (Caspi et al., 2003). 
Asked retrospectively at age 15. 
Depression of the mother Positive if any of the following true: 
self-reported having had severe 
depression (age 11); self-reported 
having taken pills for depression in the 
last three years (age 9); EDPS of at least 
10 (ages 8 months, 18 months). 
DSM-IV, children’s ages 5 to 12. Positive if biological mom 
retrospectively reported having 
the blues at or after delivery, 
asked at baseline (children’s age 7 
to 10).  
At least 7 points in the SRQ-20, as 
previously suggested (WHO, 1994), age 
11. 
Social classc Registrar’s General Classification, asked 
at birth. 
Acorn classification, ages 5 to 12. Gross household income in US$, 
age 7 to 10, ages 7 to 10. 
ABEP criteria, age 11 
CDI Children’s Depression Inventory | SDQ-C Strengths and Difficulties Questionnaire, conduct subscale | SDQ-E Strengths and Difficulties Questionnaire, 
emotional subscale | SDQ-H Strengths and Difficulties Questionnaire, hyperactivity subscale | EDPS - Edinburgh Postnatal Depression Scale | SRQ-20 Self-
reporting Questionnaire 20 | ABEP Associação Brasileira de Empresas de Pesquisa (the Brazilian Association of Research Companies) 
a. We ran a ROC curve analyses of the SDQ-C rated by parents against DAWBA in a subsample of children (n = 290). Discrimination was fair (0.77). The 
best selected cut-off was at least 7 points. 
b. Since categories of risk were heterogeneous across studies, we have decided to group categories aiming to achieve similar percentages of the population 
included in each group. Therefore, the observed effect reflects rather the relative social class (how the individual family compares to the population) than 
the absolute concept (how much does the family actually earn or possess). 
 
 
 
 
eMethods: Machine Learning approaches 
We compared the logistic regression analysis to some well-established machine learning algorithms in order to 
assess the consistency of our findings. We used the package caret (Version 6.0-73) from R software 
(https://www.R-project.org/). We selected the caret package due to its automated tuning methods for machine 
learning algorithms, which enable the selection of the best fit for each model. We assumed a diagnostic 
classification problem with the abovementioned predictors used as input data. The main objective was to train a 
set of machine learning algorithms to estimate the probability of a subject belonging to either ADHD or healthy 
control groups given previously unseen subjects’ data. In the present analysis, besides logistic regression, 
Random Forest, Artificial Neural Network, and Stochastic Gradient Boosting were used because 1) they are 
capable of modeling more complex patterns than nearly any algorithm; 2) they can handle categorical or 
continuous features; 3) they can be used on data with extremely large number of observations; 4) they can be 
used to classification prediction problems. Fforest (or decision tree forests) is an ensemble-based method that 
focuses only on ensembles of decision trees. This method was developed by Leo Breiman and Adele Cutler, and 
combines the base principles of “bagging” with random feature selection to add additional diversity to the 
decision tree models. An Artificial Neural Network (ANN) models the relationship between a set of input 
signals and an output signal using a model derived from our understanding of how a biological brain responds to 
stimuli from sensory inputs. Stochastic gradient boosting is another “bagging” procedure.5Machine learning 
approach was conducted in two phases: 1) training and validation phase and 2) test phase. In the first phase, we 
used the ALSPAC dataset to train, to validate, and to identify the best fit (parameter tuning) for each model. The 
parameters to be adjusted were 1) size and decay for ANN, 2) mtry (an optional integer specifying the number 
of features to randomly select at each split) for random forest, and 3) n.trees, interactions.depth, shrinkage, and 
n.minobsinnode for Stochastic Gradient Boosting. We used optimism bootstrapping (n=1000) as the resampling 
method and AUC to select the best fit for each model. In the second phase, we tested the selected models in E-
Risk, MTA, and Pelotas datasets.  
The parameters selected during the first phase were 1) mtry=3 for random forest, 2) size=1 and decay=0.01 for 
ANN, 3) n.trees=150, interactions.depth=1, shirinkage=0.1, n.minobsinnode=10 for Stochastic Gradient 
Boosting. eTable6 shows the AUC for each model in all test datasets. 
eFigure 1. Bias-corrected calibration plot for internal validation in the ALSPAC cohort. 
 
 
eTable 2. Predictive discrimination of the score leaving out predictors one at a time. 
  AUC 95% CI p-value 
Full model ·82 ·79 - ·84 < ·001 
- ADHD symptoms ·74 ·72 - ·76 < ·001 
- Gender ·81 ·80 - ·83 < ·001 
- Social class ·82 ·80 - ·83 < ·001 
- Single parent ·82 ·80 - ·83 < ·001 
- ODD/CD ·81 ·80 - ·83 < . ·001 
- Childhood maltreatment ·82 ·80 - ·83 < ·001 
- Depressive symptoms ·82 ·79 - ·83 < ·001 
- Mother’s depression ·81 ·79 - ·84 < ·001 
- IQ ·81 ·79 - ·83 < ·001 
AUC Area under the Curve | CI Confidence Interval | ADHD Attention-deficit/Hyperactivity Disorder | ODD 
Oppositional Defiant Disorder | CD Conduct Disorder 
 
 
 
 
 
 
 
eTable 3. Sensitivity, specificity, positive and negative predictive values at selected risk cut-offs. 
 Sensitivity Specificity PPV NPV 
Probability >= 10% 72·4% 74·3% 22·9% 96·3% 
Probability >= 20% 45·1% 91·0% 34·4% 94·0% 
Probability >= 30% 30·3% 96·0% 44·5% 92·9% 
Probability >= 40% 20·4% 98·1% 52·4% 92·1% 
Probability >= 50% 11·1% 99·0% 54·5% 91·4% 
Probability >= 60% 6·0% 99·6% 61·8% 91·0% 
PPV+ Positive Predictive Value NPV Negative Predictive Value 
 
eTable 4. The assessment of the confounding effect of twin pairs in the E-Risk. 
 AUC 95% CI p-value 
Random non-siblings 1 (n = 1020) ·75 ·70 - ·80 < 0·001 
Random non-siblings 2 (n = 1020) ·75 ·70 - ·80 < 0·001 
         AUC Area under the Curve | CI Confidence Interval Note: We tested the risk score in the E-Risk sample 
in subgroups of randomly selected non-sibling participants. 
eFigure 2: Variation of predicted probabilities within fixed levels of ADHD symptoms  
 
 
 
 
 
 
 
eTable 5. Performance of the score for Major Depression Disorder or Anxiety Disorders in young 
adulthood¹. 
 AUC 95% CI p-value vs. ADHD (p-
value)² 
Anxiety Disorders ·52 ·47 - ·59 ·72 < 0·001 
Major Depressive Disorder ·56 ·52 - ·59  ·001 < 0·001 
Alcohol Use Disorder .58 .54 - .62 < .001 < .001 
Marijuana Use Disorder .67 .60 - .73 < .001 .03 
AUC Area under the Curve | CI Confidence Interval | ADHD Attention-deficit/Hyperactivity Disorder  
1. Tested in the E-Risk sample. 
2. Tested against the performance of the score for predicting ADHD in the E-Risk cohort 
 
eTable 6. Performance of the predictive model using Machine Learning approaches. 
 Area Under the Curve (95% Confidence Interval) 
 ALSPAC E-Risk MTA Pelotas 
Logistic Regression (original) ·82 (·80 - ·83) ·75 (·71 - ·78) ·76 (·73 - ·80) ·57 (·54 - ·60) 
Random Forest ·80 (·74 - ·87) ·70 (·67 - ·74) ·72 (·68 – ·76) ·56 (·53 - ·59) 
Stochastic Gradient Boosting ·81 (·78 - ·83) ·74 (·71 – ·77) ·76 (·72 - ·79) ·57 (·55 – ·60) 
Artificial Neural Network ·81 (·77 - ·85) ·74 (·70 - ·77) ·76 (·72 - ·80) ·58 (·55 - ·61) 
 
eTable 7. A comprehensive model including all samples 
We have developed an alternative approach using all data at once, including site as a tenth predictor. 
Predictor OR (BC 95% CI) BC p-value 
Female sex 1·06 (·94 – 1·21) ·349 
Social class  - - 
Higher reference  
Middle 1·04 (·87– 1·24) ·639 
Lower 1·02 (·84 – 1·23) ·850 
Single parent family 1·09 (·94 – 1·26) ·262 
Childhood maltreatment - - 
None reference - 
Probable 1·39 (1·21 – 1·59) < ·001 
Severe 1·98 (1·65 – 2·37) < ·001 
Oppositional Defiant Disorder or Conduct Disorder 1·14 (·97 – 1·34) ·104 
Mother’s depression 1·12 (·99 – 1·28) ·083 
ADHD symptoms – 0-25th  2·19 (1·55 – 3·11) < ·001 
ADHD symptoms – 25-50th  1·21 (1·09 – 1·34) < .001 
ADHD symptoms – 50-75th  1·11 (1·06 – 1.16) < .001 
ADHD symptoms – 75-100th  1.07 (1.04 – 1·10) < ·001 
Intelligence quotienta  ·91 (·88 – 1·10) < ·001 
Depressive symptoms 1·04 (·98 – 1·10) ·180 
Site    
ALSPAC reference - 
E-Risk ·99 (·80 – 1·22) ·944 
Pelotas ·71 (·59 - ·85) < ·001 
MTA 2·35 (1·89 – 2·92) < ·001 
BC Bootstrap corrected   
a. We report the OR for a 10-point change in the intelligence quotient scale. 
 
Overall Area Under the Curve: ·74 (·73 - ·76), p < ·001 (Bootstrap optimism-corrected: ·73) 
We also ran a comprehensive model including all two-way interactions between site and predictor variables, 
with an AUC of ·78 (available upon request). 
eFigure 3. Bias-corrected calibration plot for internal validation in the comprehensive model. 
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